Cytokine evaluation in individuals with low back pain using discographic lavage
Abstract
Background context
The pathophysiology underlying degenerative disc disease and its implication in painful syndromes remain unclear. However, spine magnetic resonance imaging (MRI) can demonstrate changes in disc water content and the annulus; provocative discography purportedly identifies degenerate discs causing serious low back pain; and biochemical assays have identified local inflammatory markers. No study to date has correlated pain on disc injection during discography evaluation with relevant MRI findings and biochemical markers.
Purpose
The purpose of this study was to correlate concordant pain on during discography to biochemical markers obtained by disc lavage and MRI findings.
Study design
This is a Phase 1 Diagnostic Test Assessment Cohort Study (Sackett and Haynes).
Patient sample
The patient sample included 21 symptomatic patients with suspected discogenic pain and three Phase 1 control subjects.
Outcome measures
The outcome measures included discography pain scores, MRI degenerative grades, and immunoreactivity to various inflammatory cytokine concentrations present in disc lavage samples.
Methods
Twenty-one symptomatic patients with lumbar degenerative disc disease and three control subjects underwent discography, MRI, and biochemical analysis of disc lavage fluid. Lumbar MRI was scored for Pfirrmann grading of the lumbar discs, and annular disruption was identified by nuclear disc lavage. Disc lavage samples were analyzed for biochemical markers by high-sensitivity immunoassay.
Results
Eighty-three discs from 24 patients were studied: 67 discs from 21 patients with axial back pain (suspected discogenic pain group) and 16 discs from 3 scoliosis patients without back pain (Phase 1 control subjects). Among the biochemical markers surveyed, interferon gamma (IFN-γ) immunoreactivity was most consistently identified in patients with axial back pain. Discs with annular disruption and concordant pain reproduction at a visual analog scale of 7 to 10/10 had greater IFN-γ immunoreactivity than those without this finding (p=.003); however, at least some IFN-γ immunoreactivity was found in all but one disc in the symptomatic group.
Conclusions
Among the potential inflammatory markers tested in this Phase 1 study, IFN-γ immunoreactivity was most commonly elevated in discogram “positive” discs but absent in asymptomatic controls. However, this marker was also frequently elevated in degenerative but “negative” discography discs. From these findings, Phase 2 and Phase 3 validity studies are reasonable to pursue. Phase 4 utility studies may be performed concurrently to assess this method's predictive value in outcome studies.
Keywords: Intervertebral disc, Cytokines, Interferon gamma, Discography, Low back pain
To access this article, please choose from the options below
FDA device/drug status: not applicable.
Author disclosures: JMC (stock ownership, including options and warrants, Cytonics; scientific advisory board, Cytonics; research: staff/materials, Cytonics); SRG (stock ownership, including options and warrants, Cytonics Inc; scientific advisory board, Cytonics); MWR (stock ownership, including options and warrants, Cytonics; private investments, including venture capital, start-ups, Cytonics); VGC (stock ownership, including options and warrants, Cytonics Corp; scientific advisory board, Cytonics Corp); MSA (royalties, Stanford University; stock ownership, including options and warrants, Cytonics; consulting, Trigemina Inc, Cortex Inc, Vertex Inc; scientific advisory board, Cytonics Inc; research: investigator salary, Scientific Imaginetics; research: staff/materials, Scientific Imaginetics); EJC (consulting, Medtronic; scientific advisory board, Intrinsic Orthopedics, Cytonics; other office, Bioassetts; grants, AO Foundation; fellowship support, DePuy Spine); DCY (stock ownership, including options and warrants, Cytonics Inc; scientific advisory board, Cytonics, Inc); GJS (stock ownership, including options and warrants, Cytonics Corp; private investments, including venture capital, start-ups, K2 Medical; board of directors, Cytonics; scientific advisory board, Cytonics; other office, Chairman).
PII: S1529-9430(09)01127-9
doi:10.1016/j.spinee.2009.12.007
© 2010 Elsevier Inc. All rights reserved.
